Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Ironwood Pharmaceuti (IRWD)

Ironwood Pharmaceuti (IRWD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,538,988
  • Shares Outstanding, K 159,978
  • Annual Sales, $ 428,410 K
  • Annual Income, $ 21,510 K
  • 60-Month Beta 1.49
  • Price/Sales 3.55
  • Price/Cash Flow 16.43
  • Price/Book N/A
Trade IRWD with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate 0.14
  • Number of Estimates 4
  • High Estimate 0.17
  • Low Estimate 0.10
  • Prior Year 0.40
  • Growth Rate Est. (year over year) -65.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.65 +13.92%
on 10/01/20
10.71 -7.94%
on 10/16/20
+0.86 (+9.62%)
since 09/30/20
3-Month
8.63 +14.25%
on 09/29/20
10.80 -8.70%
on 08/19/20
+0.44 (+4.67%)
since 07/30/20
52-Week
7.99 +23.40%
on 03/18/20
14.10 -30.07%
on 12/26/19
+0.43 (+4.56%)
since 10/30/19

Most Recent Stories

More News
Ironwood Pharmaceuticals to Host Third Quarter 2020 Investor Update Call

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its third quarter 2020 investor update conference call and webcast at 4:30 p.m. Eastern Time on Thursday, November 5, 2020. Individuals...

IRWD : 9.89 (+2.81%)
Jazz Pharma's Xywav Succeeds in Idiopathic Hypersomnia Study

Jazz Pharmaceuticals (JAZZ) posts favorable top-line results from a phase III study on Xywav oral solution, which is being evaluated to treat adult patients with idiopathic hypersomnia. Shares rise.

IRWD : 9.89 (+2.81%)
JAZZ : 144.17 (-1.00%)
ONTX : 0.2668 (+2.62%)
ACRS : 3.80 (-0.78%)
Ironwood to End IW-3718 Development After Study Failure

Ironwood's (IRWD) pipeline candidate, IW-3718, fails to meet primary endpoint in a phase III study evaluating it in patients with refractory GERD.

IRWD : 9.89 (+2.81%)
AZN : 50.16 (-1.78%)
ABBV : 85.19 (+5.60%)
CTLT : 87.86 (-1.71%)
Constipation Treatment Drug Market Report 2026 Contains Review on Industry Size, Key Leading Companies and Opportunity by Geography

The "" 2020 report includes the market strategy, market orientation, expert opinion and knowledgeable information. The Constipation Treatment Drug Industry Report is an in-depth study analyzing the current...

ABT : 105.07 (+0.07%)
ALBO : 31.53 (-3.61%)
IRWD : 9.89 (+2.81%)
PBH : 33.03 (-0.66%)
SCMP : 18.05 (+0.28%)
SGYP : 0.03 (-52.00%)
VRX.TO : 30.80 (-3.33%)
Heron's (HRTX) Pain Drug Zynrelef Gets EU Approval, Shares Up

Heron's (HRTX) Zynrelef gains a marketing nod from the European Commission for managing postoperative pain in surgical wounds among adult patients. Stock rises.

IRWD : 9.89 (+2.81%)
BLRX : 2.0000 (+35.14%)
ALDX : 6.69 (+6.02%)
HRTX : 16.31 (+1.68%)
Ironwood to Discontinue IW-3718 Development Program Following Results from Planned Efficacy Assessment

--- Ironwood plans to implement organizational restructuring, resulting in expected headcount reduction of approximately 100 full-time employees, or nearly 35% of current workforce -

IRWD : 9.89 (+2.81%)
Pacira (PCRX) Gains Positive CHMP Opinion for Exparel in EU

The CHMP gives a positive opinion recommending an approval for Pacira's (PCRX) Exparel (bupivacaine liposome injectable suspension) to treat postsurgical pain.

IRWD : 9.89 (+2.81%)
PCRX : 52.30 (-1.54%)
INFI : 1.0500 (-4.55%)
ALDX : 6.69 (+6.02%)
Constipation Treatment Drug Market By Current Industry Status, Growth Opportunities, Top Key Players, Target Audience And Forecast To 2026

A recent report provides crucial insights along with application based and forecast information in the Global Constipation Treatment Drug Market. The report provides a comprehensive analysis of key factors...

ABT : 105.07 (+0.07%)
ALBO : 31.53 (-3.61%)
BAYRY : 11.7200 (-2.17%)
IRWD : 9.89 (+2.81%)
PBH : 33.03 (-0.66%)
SCMP : 18.05 (+0.28%)
SGYP : 0.03 (-52.00%)
VRX.TO : 30.80 (-3.33%)
Ironwood Pharmaceuticals to Participate in Upcoming September Investor Conferences

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will participate in fireside chats at two upcoming virtual investor conferences in September:

MS : 48.25 (+0.27%)
IRWD : 9.89 (+2.81%)
Surging Earnings Estimates Signal Upside for Ironwood (IRWD) Stock

Ironwood (IRWD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

IRWD : 9.89 (+2.81%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Ironwood Pharmaceuticals is an entrepreneurial pharmaceutical company that discovers, develops, and intends to commercialize innovative human medicines. The Company's first in class compound, Linaclotide, is being evaluated in a confirmatory Phase 3 program for the treatment of irritable bowel syndrome...

See More

Key Turning Points

2nd Resistance Point 9.95
1st Resistance Point 9.79
Last Price 9.89
1st Support Level 9.42
2nd Support Level 9.21

See More

52-Week High 14.10
Fibonacci 61.8% 11.77
Fibonacci 50% 11.05
Fibonacci 38.2% 10.32
Last Price 9.89
52-Week Low 7.99

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar